

kandidátním lékem pro časově omezenou léčbu CHD. Jeho účinnost a bezpečnostní spektrum je nutné prověřit v dalších klinických studiích (3).

Tento doporučený postup byl schválen výbory SIL ČLS JEP a ČHS ČLS JEP v roce 2023.

LITERATURA

- Husa P, et al. Diagnosis and therapy of hepatitis B virus infection: Czech national guidelines. Date of release: September 2017. *Klin. Mikrobiol. Infekční Lek.* 2017;23:148-164.
- Husa P, et al. Diagnosis and therapy of hepatitis B virus infection – Czech national guidelines. *Gastroenterol. Hepatol.* 2017;71:419-437.
- Brunetto MR, et al. EASL Clinical Practice Guidelines on hepatitis delta virus. *J. Hepatol* 2023;79:433-460.
- Walker PJ, et al. Changes to virus taxonomy and to the International Code of Virus Classification and Nomenclature ratified by the International Committee on Taxonomy of Viruses (2021). *Arch. Virol.* 2021;166:2633-2648.
- Papatheodoridi M, Papatheodoridis GV. Is hepatitis delta underestimated? *Liver Int.* 2021;41:38-44.
- Miao Z, et al. Estimating the Global Prevalence, Disease Progression, and Clinical Outcome of Hepatitis Delta Virus Infection. *J. Infect., Dis.* 2020;221:1677-1687.
- Chen H-Y, et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. *Gut.* 2019;68:512-521.
- Stockdale AJ, et al. The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis. *J. Hepatol.* 2020;73:523-532.
- Lampertico P, et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. *J. Hepatol.* 2017;67:370-398.
- Sarin SK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. *Hepatol. Int.* 2016;10:1-98.
- Terrault NA, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. *Hepatology.* 2018; 67:1560.
- Palom A, et al. Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis D. *JHEP Rep.* 2022;4:100547.
- Buti M, Esteban R, Jardí R, et al. Serological diagnosis of acute delta hepatitis. *J. Med. Virol.* 1986;18:81-85.
- Romeo R, et al. High Serum Levels of HDV RNA Are Predictors of Cirrhosis and Liver Cancer in Patients with Chronic Hepatitis Delta. *PLOS ONE.* 2014;9:e92062.
- Ricco G, et al. Quantification of serum markers of hepatitis B (HBV) and Delta virus (HDV) infections in patients with chronic HDV infection. *J. Viral Hepat.* 2018;25:911-919.
- Palom A, et al. One-quarter of chronic hepatitis D patients reach HDV-RNA decline or undetectability during the natural course of the disease. *Aliment. Pharmacol. Ther.* 2021;54:462-469.
- Caredda F, et al. Incidence of Hepatitis Delta Virus Infection in Acute HBsAg-Negative Hepatitis. *J. Infect., Dis.* 1989;159:977-979.
- Kamal H, et al. Long-Term Study of Hepatitis Delta Virus Infection at Secondary Care Centers: The Impact of Viremia on Liver-Related Outcomes. *Hepatology.* 2020;72:1177.
- Berzigotti A, et al. Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. *Hepatology.* 2011;54:555-561.
- El-Serag HB, Hampel H, Javadi F. The Association Between Diabetes and Hepatocellular Carcinoma: A Systematic Review of Epidemiologic Evidence. *Clin. Gastroenterol. Hepatol.* 2006;4:369-380.
- Zachou K, et al. Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. *Liver Int.* 2010;30:430-437.
- Asselah T, et al. Improving the Accuracy of Non-Invasive Test for prediction of cirrhosis in CHD: insight from 230 patients from D-liver study. *J Hepatol.* 2021;75:S637-S638
- Diaz G, et al. Molecular Signature and Mechanisms of Hepatitis D Virus–Associated Hepatocellular Carcinoma. *Mol. Cancer. Res.* 2018;16:1406-1419.
- Caviglia GP, et al. The hepatitis D virus in Italy. A vanishing infection, not yet a vanished disease. *J. Adv. Res.* 2021;33:183-187.
- Roulot D, et al. Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta. *J. Hepatol.* 2020;73:1046-1062.
- Romeo R, et al. A 28-Year Study of the Course of Hepatitis Δ Infection: A Risk Factor for Cirrhosis and Hepatocellular Carcinoma. *Gastroenterology.* 2009;136:1629-1638.
- Osiowy C, et al. Molecular epidemiology and clinical characteristics of hepatitis D virus infection in Canada. *JHEP Rep.* 2022;4:100461.
- Tzartzeva K, et al. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. *Gastroenterology.* 2018;154:1706-1718.e1.
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. *J. Hepatol.* 2018;69:182-236.
- Ricco G, et al. Highly dynamic changes of regional HBV epidemiology over two decades. *Dig. Liver, Dis.* 2023;55:519-526.
- Abdrakhman A, Ashimkhanova A, Almawi WY. Effectiveness of pegylated interferon monotherapy in the treatment of chronic hepatitis D virus infection: A meta-analysis. *Antiviral Res.* 2021;185:104995.
- Wedemeyer H, et al. A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D. *N. Engl. J. Med.* 2023;389:22-32.
- Zhang Z, et al. Hepatitis D virus-induced interferon response and administered interferons control cell division-mediated virus spread. *J. Hepatol.* 2022;77:957-966.
- Bogomolov P, et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study. *J. Hepatol.* 2016;65:490-498.
- Wedemeyer H, et al. Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial. *Lancet Infect. Dis.* 2023;23:117-129.
- Wedemeyer H, et al. GS-13-Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in cwith PEG-interferon Alpha 2a in patients with chronic HBV/HDV co-infection. *J. Hepatol.* 2019;70:e81.
- Stoll F, et al. Metabolic Effect of Blocking Sodium-Taurocholate Co-Transporting Polypeptide in Hypercholesterolemic Humans with a Twelve-Week Course of Bulevirtide—An Exploratory Phase I Clinical Trial. *Int. J. Mol. Sci.* 2022;23:15924.
- Schaper M, et al. Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D. *J. Hepatol.* 2010;52:658-664.
- Samuel D, et al. Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis. *Hepatology.*1995;21:333-339.
- Akarsu M, et al. Recommendations for Hepatitis B Immunoglobulin and Antiviral Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation. *Turk. J. Gastroenterol.* 2021;2:712-719.